about
Cystatin C: a candidate biomarker for amyotrophic lateral sclerosisAmyotrophic lateral sclerosis: an emerging era of collaborative gene discoveryWhole-brain analysis of amyotrophic lateral sclerosis by using echo-planar spectroscopic imaging.Proteomic analysis of plasma from Portuguese patients with familial amyotrophic lateral sclerosis.Comparative proteomic profiling of cerebrospinal fluid between living and post mortem ALS and control subjects.Galectin-3 is a candidate biomarker for amyotrophic lateral sclerosis: discovery by a proteomics approach.Autoimmunity in amyotrophic lateral sclerosis: past and present.Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease.Systematic screens for human disease genes, from yeast to human and back.Protein biomarkers for amyotrophic lateral sclerosis.Structural imaging differences and longitudinal changes in primary lateral sclerosis and amyotrophic lateral sclerosis.Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases.Scrutinizing enrollment in ALS clinical trials: room for improvement?Proteomics of human neurodegenerative diseasesRecent advances in metabolomics in neurological disease, and future perspectives.Oral administration of memantine prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis.Proposed BioRepository platform solution for the ALS research community.Serum level of CNTF is elevated in patients with amyotrophic lateral sclerosis and correlates with site of disease onset.Improving access to medicines: empowering patients in the quest to improve treatment for rare lethal diseases.
P2860
Q28476466-3073C103-EF0F-4018-A2C3-A96096C318C1Q30444138-5AED329D-3970-4E73-BC24-1C1AE63AA257Q30586692-35202760-925C-4B4C-BA35-EFAE10284653Q33349895-2D538FF1-1463-4841-B65E-EF8FBD52A1BDQ33691896-98FD5C2D-3AB4-434A-9D68-190965C6C8D6Q34168523-8B4A7627-EC04-4E33-AC64-9AB75A8A81DEQ35147143-04A098E1-CD0F-42A5-B1C7-909EF9039057Q36615226-4A4D1BB5-413E-42EB-A3EC-B146EE679D24Q37030590-10A53928-6DA3-40DB-9E4E-53167445B432Q37157841-79A3FDE8-584A-4070-84DA-5F6B3C0544A7Q37185640-DF35E138-32B8-4E33-A542-624CC42AE20AQ37206262-4D1FFCD2-25B1-4869-A69D-405408B335C3Q37209736-4A36A9F0-C895-48EA-8D5A-0E3923199D88Q37260477-7D63D039-8902-4B4C-90D4-A90274D5F19DQ38110171-44729411-0434-4E7D-A61E-0769879438EDQ42849360-C585800D-72EF-4486-B6E8-AB8B514D1D0EQ45344955-C5A7E5F4-956D-476E-B7A3-4E21B8E03FB4Q46692698-65846378-C681-49F2-95BB-7C1C6ECFF293Q47870601-9E7C1371-707A-47B9-A14A-F19A79D3D6BB
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Biomarkers for amyotrophic lateral sclerosis.
@ast
Biomarkers for amyotrophic lateral sclerosis.
@en
type
label
Biomarkers for amyotrophic lateral sclerosis.
@ast
Biomarkers for amyotrophic lateral sclerosis.
@en
prefLabel
Biomarkers for amyotrophic lateral sclerosis.
@ast
Biomarkers for amyotrophic lateral sclerosis.
@en
P2860
P356
P1476
Biomarkers for amyotrophic lateral sclerosis.
@en
P2093
Robert Bowser
P2860
P304
P356
10.1586/14737159.6.3.387
P577
2006-05-01T00:00:00Z